Literature DB >> 1586797

Low dose oxybutynin for the unstable bladder.

J Malone-Lee, D Lubel, G Szonyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1586797      PMCID： PMC1881729          DOI： 10.1136/bmj.304.6833.1053

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  1 in total

1.  The pharmacokinetics of oxybutynin in man.

Authors:  J Douchamps; F Derenne; A Stockis; D Gangji; M Juvent; A Herchuelz
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953
  1 in total
  6 in total

Review 1.  Clinical pharmacology of old age syndromes.

Authors:  C Broadhurst; K C M Wilson; M T Kinirons; A Wagg; J K Dhesi
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

2.  Selecting a medical therapy for overactive bladder.

Authors:  H Henry Lai; Timothy B Boone; Rodney A Appell
Journal:  Rev Urol       Date:  2002

3.  CUA guideline on adult overactive bladder.

Authors:  Jacques Corcos; Mikolaj Przydacz; Lysanne Campeau; Gary Gray; Duane Hickling; Christiane Honeine; Sidney B Radomski; Lynn Stothers; Adrian Wagg; Frcp Lond
Journal:  Can Urol Assoc J       Date:  2017-05-09       Impact factor: 1.862

Review 4.  Economics of lower urinary tract symptoms (LUTS) in older people.

Authors:  U Azam; M Castleden; D Turner
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 5.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 6.  Pharmacologic treatment for detrusor overactivity.

Authors:  H Henry Lai; Timothy B Boone; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2002-10       Impact factor: 2.862
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.